Archive: 10/06/2013

AstraZeneca in $560 m deal for respiratory firm

British drugmaker AstraZeneca PLC says it is to acquire Pearl Therapeutics Inc., a Redwood-City, California-based company involved in therapies for asthma and chronic obstructive pulmonary disease for at least $560 million.

Cost-effective: Universal HIV testing in India

In India most people who are HIV positive don't know it, yet testing and treatment are relatively cheap and available. It would therefore meet international standards of cost-effectiveness—and save millions of lives for ...

Clearing the BAR to oral vaccines

A new technology under development by an academic–industry partnership protects oral vaccines from destruction by the digestive system.

page 6 from 8